Clinical studies of drug reversal of hypertensive left ventricular hypertrophy

American Journal of Hypertension

Volumn 3, Issue 6, 1990, Pages 512-517

  Liebson, Philip R ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Calcium channel blockers; Diuretics; Left ventricular hypertrophy; Methyldopa; Vasodilators; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METHYLDOPA; PERIPHERAL VASODILATING AGENT;

CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; CARDIOMEGALY; CLINICAL TRIALS; COMPARATIVE STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART VENTRICLE; HUMAN; HYPERTENSION;

EID: 0025066161     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/3.6.512     Document Type: Article

References (15)

1. Kannel WB, Gordon T, Offutt D: Left ventricular hyper-trophy by electrocardiogram: prevalence, incidence and mortality in the Framingham study. Ann Int Med 1969;71:89–105.
2. Devereux RB: Importance of left ventricular mass as a predictor of cardiovascular morbidity in hypertension. Am J Hypertens 1989;2:650–654.
3. Messerli FH, Oren S, Grossman E: Left ventricular hypertrophy and antihypertensive therapy. Drugs 1988;35(suppl 5):27–33.
4. Hypertension Detection and Followup Program Cooper-ative Group: Five year findings of the hypertension de-tection and followup program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension 1985;7:105–112.
5. McMahon A, Collins G, Rautahaharju P, et al: Electro-cardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1989;63:202–210.
6. Devereux RB, Reichek N: Echocardiographic determina-tion of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613–618.
7. Hammond IW, Devereux RB, Alderman MH, et al: The prevalence and correlates of echocardiographic left ven-tricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986;7:639–650.
8. Levy D, Anderson KM, Savage DD, et al: Echocardio-graphically detected left ventricular hypertrophy: preva-lence and risk factors. Ann Int Med 1988;108:7–13.
9. Liebson PR, Savage DD: Echocardiography in hyperten-sion: a review. II. Echocardiographic studies of the effects of antihypertensive agents on left ventricular wall mass and function. Echocardiography 1987;4:215–249.
10. Schlant RC, Felner JM, Blumenstein BA, et al: Echocar-diographic documentation of regression of left ventricular hypertrophy in patients treated with essential hyper-tension. Eur Heart J 1982;suppl A:171 -175.
11. Leenen FHH, Smith DL, Farkas RM, et al: Vasodilators and regression of left ventricular hypertrophy. Am J Med 1987;72:969–978.
12. Grimm RH Jr: The drug treatment of mild hypertension in the Multiple Risk Factor Intervention Trial. A review. Drugs 2986;31(suppl 1):13–21.
13. Szlachic J, Tubau JF, Vollmer C, Massie BM: Effects of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension. Am J Cardiol 1989;63:198–201.
14. White WB, Schulman P, Karimeddin MK, Smith VE: Re-gression of left ventricular mass is accompanied by im-provement in rapid left ventricular filling following anti-hypertensive therapy with metroprolol. Am Heart J 1989;117:145–150.
15. Stamler J, Prineas RJ, Neaton JD, et al: Background and design of the New US Trial on Diet and Drug Treatment of “Mild Hypertension” (TOMHS). Am J Cardiol 1987;59:51G-60G.